Insulet Stock: A High-Quality Growth Story At A Reasonable PEG (NASDAQ:PODD)
· seekingalpha.com
Insulet (PODD) Buy thesis: Omnipod automation drives recurring revenue, low pump penetration fuels growth; valuation suggests 60% upside. See more.
Insulet ( PODD ) has pulled back 44% in the last year despite continuing to show some of the strongest growth metrics in the medtech industry. While the market ...